Active

Deconib

Switched

BE0425919575

Rechtspersoon Public limited company 1 establishment

Aalterbaan 119, 9990 Maldegem Activiteiten van holdings

Active for

42 year, 8 months

Financials

Financial year 2025

Worth noting

  • Little cash and receivables against the short-term debts.

Gross margin

€ 1.2 million

▲ 5% vs 2024

Profit

Growing

€ 279,063

▲ 38% vs 2024

Debts

Normal

€ 6.2 million

▲ 6% vs 2024

Deconib from Maldegem, company number BE0425919575, closed financial year 2025 with a result of € 279,063 after tax. For that financial year Deconib recorded a gross margin of € 1.2 million and equity of € 3.3 million. Compared with financial year 2024, the result moved from € 202,738 to € 279,063. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 29, 2026.

What happened at Deconib?

What happened at Deconib in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • New annual accounts for financial year 2025: profit of € 279,063 (▲ 38% vs 2024). filed late Source: NBB ↗
  • DENCON BV became a director. NBB
  • FRONT ROW MANAGEMENT BV became a director. NBB
  • New establishment in Maldegem. KBO
  • Start of the company according to the CBE. KBO

In short

From € 46,549 loss in 2021 to € 279,063 profit in 2025.

Paid € 602,166 in corporate taxes since 2021.

Best year ever: 2025, with € 279,063 profit.

On average € 1.2 million of value added per employee in 2025.

A new publication or filing at Deconib? We notify you, reason included.

Follow Deconib

Need more data?

History

Every financial year, as far back as the National Bank goes.

Buffer

How long does the company survive without income?

Credit limit

Indicative credit limit, computed from the real figures.

Alerts

New annual account: profit halved. New
Gazette: capital increase of 250k. New

News about who you follow, reason included.

Databakkes Pro · first month free

Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.

Management

Behind Deconib are DENCON BV and FRONT ROW MANAGEMENT BV. It owns 100% of VAN LANDSCHOOT and 100% of DECOMAT itself.

See the full network in the app

Directors

According to the 2025 annual accounts

DENCON BV

Managing director · represented by Dennis De Coninck

Also active at: Matrassenfabriek Van Landschoot, NEW-HERMAT, DECOMAT

since 2021

FRONT ROW MANAGEMENT BV

Managing director · represented by Rowany De Coninck

Also active at: Matrassenfabriek Van Landschoot, NEW-HERMAT, DECOMAT

since 2021

Establishments

Establishment units

Physical locations of this company

Registered office

Aalterbaan 119

9990 Maldegem

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number
0425.919.575
VAT number
BE 0425.919.575
Registered office
Aalterbaan 119, 9990 Maldegem
Names & denominations
Deconib
Enterprise type
Rechtspersoon
Legal form
Public limited company
Legal situation
Normale toestand
Start date
21 December 1983
Peppol
Active · Active since 13 Oct 2025
Activities · NACE

Activiteiten van holdings

Marktonderzoekbureaus

Holdings

Markt- en opinieonderzoek

Verhuur en lease van machines en installaties voor de bouwnijverheid en de weg- en waterbouw

Frequently asked questions

What is the enterprise number of Deconib?
The enterprise number of Deconib is BE0425919575.
What is the address of Deconib?
The registered office of Deconib is located at Aalterbaan 119, 9990 Maldegem.
When was Deconib founded?
Deconib was founded on 21 December 1983.
What is the main activity of Deconib?
The main activity of Deconib is "Activiteiten van holdings" (NACE code 64210).
Does Deconib have a website?
No website is currently known for Deconib.
How much profit did Deconib make in 2025?
Deconib posted a profit after taxes of € 279,063 in financial year 2025.
What is the revenue of Deconib?
As a small company, Deconib is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,210,334.
How many employees does Deconib have?
According to the 2025 annual accounts, Deconib has 1 full-time equivalents (FTE).
Where can I find the annual accounts of Deconib?
Deconib files its annual accounts with the Central Balance Sheet Office of the National Bank of Belgium. The key figures for recent financial years are available for free on this page.
Who are the directors of Deconib?
According to the 2025 annual accounts, the directors of Deconib are: DENCON BV, FRONT ROW MANAGEMENT BV.
Who owns Deconib?
Behind Deconib are DENCON BV and FRONT ROW MANAGEMENT BV. It owns 100% of VAN LANDSCHOOT and 100% of DECOMAT itself.